The Progressive Supranuclear Palsy Clinical Deficits Scale

Area of Science:

• Neurology
• Clinical Assessment
• Movement Disorders

Background:

• No validated clinical measure exists for the wide range of Progressive Supranuclear Palsy (PSP) phenotypes.
• Accurate assessment tools are crucial for monitoring disease progression and treatment efficacy in PSP.

Purpose of the Study:

• To develop and validate the Progressive Supranuclear Palsy Clinical Deficits Scale (PSP-CDS) for assessing PSP across its diverse clinical presentations.
• To create a standardized tool for monitoring clinical deficits in PSP patients.

Main Methods:

• The PSP-CDS was designed to evaluate seven domains: Akinesia-rigidity, Bradyphrenia, Communication, Dysphagia, Eye movements, Finger dexterity, and Gait & balance.
• The scale was administered to 164 patients meeting MDS-PSP criteria in two independent, multicenter studies, with both cross-sectional and 12-month longitudinal follow-up.
• Standardized user guidelines were developed to ensure consistent application of the scale.

Main Results:

• The PSP-CDS demonstrated ease of use, with a mean completion time of 4 minutes.
• The scale showed strong correlations with existing measures (e.g., PSP Rating Scale, R=0.88) and acceptable psychometric properties (Cronbach's alpha=0.75, inter-rater reliability=0.96, test-retest stability=0.99).
• Significant 12-month changes were detected using the PSP-CDS, indicating its sensitivity to disease progression.

Conclusions:

• The Progressive Supranuclear Palsy Clinical Deficits Scale (PSP-CDS) is a clinically sound and rapidly administered tool.
• The PSP-CDS is suitable for both clinical care and research applications in Progressive Supranuclear Palsy.
• This scale aids in monitoring PSP progression and can inform therapeutic trial design.